MAintain Functions and INTrinsec capacities with Aging : Preventive and Personalized INterventional Research

  • Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.  Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019. 380(15):1408-1420. doi: 10.1056/NEJMoa1812840. abstract
  • de Souto Barreto P, Rolland Y, Vellas B, Maltais M. Association of Long-term Exercise Training With Risk of Falls, Fractures, Hospitalizations, and Mortality in Older Adults: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019. 179(3):394-405. doi: 10.1001/jamainternmed.2018.5406. Abstract
  • Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoine T, Dartigues JF, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere JP, Weiner M, Carrié I, Ousset PJ, Vellas B; MAPT Study Group. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.  Lancet Neurol. 2017 May;16(5):377-389. doi:10.1016/S1474-4422(17)30040-6. abstract
  • Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016 Apr;15(5):455-532. doi: 10.1016/S1474-4422(16)00062-4. abstract
  • Andrieu S, Coley NLovestone S,  Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015.14(9):926-944. abstract
  • Gallini A, Gardette V, Oumouhou N, Andrieu S, Donohue J.M. Evolution of General Practitioners' Preferences for Antipsychotics in France, 2003-2010. Psychiatric services. 2015. 66(4):434-37 abstract
  • Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol.  2014. 13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. abstract
  • Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014. 370(4):311-21. doi: 10.1056/NEJMoa1312889. abstract
  • Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; for the GuidAge Study Group. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012.11(10):851-859. doi: 10.1016/S1474-4422(12)70206-5. abstract
  • Coley N, Gardette V, Cantet C, Gillette-Guyonnet S, Nourhashemi F, Vellas B, Andrieu S. How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients ?  Curr Alzheimer Res. 2011. 8(4):421-33. abstract
  • Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011. 76(3):280-6. doi: 10.1212/WNL.0b013e318207b1b9. abstract
  • Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Giraudeau B, Cantet C, Coley N, Vellas B; PLASA Group. Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). BMJ. 2010. 340:c2466. doi: 10.1136/bmj.c2466. abstract
  • Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, Grand A, Monstastruc JL, Vellas B. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs. 2010 May 1;24(5):431-42. doi: 10.2165/11318010-000000000-00000. abstract
  • Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B for REAL.fr Study Group. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology. 2009. 73(17):1359-66. doi: 10.1212/WNL.0b013e3181bd80e9.
  • Rolland Y, Lauwers-Cances V, Cristini C, van Kan GA, Janssen I, Morley JE, Vellas B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr. 2009. 89(6): 1895-900. doi: 10.3945/ajcn.2008.26950. abstract
  • Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009. 16(2): 235-70. doi: 10.3233/JAD-2009-0971.
  • Rolland Y, Abellan van Kan G, Nourhashemi F, Andrieu S, Cantet C, Guyonnet-Gillette S, Vellas B. An abnormal "one-leg balance" test predicts cognitive decline during Alzheimer's disease. J Alzheimers Dis. 2009. 16(3): 525-31. doi: 10.3233/JAD-2009-0987.abstract
  • Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev. 2008. 30:35-66. doi: 10.1093/epirev/mxn010. abstract
  • Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; for the European Task Force Group. Endpoints for trials in Alzheimer's disease: a European task force consensus.  Lancet Neurol. 2008. 7(5): 436-450. doi: 10.1016/S1474-4422(08)70087-5.. abstract